Compare UXIN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | Netherlands |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 262.5M |
| IPO Year | 2018 | 2014 |
| Metric | UXIN | PRQR |
|---|---|---|
| Price | $0.88 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.78 |
| AVG Volume (30 Days) | 170.4K | ★ 851.5K |
| Earning Date | 09-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.68 | $8.25 |
| Revenue Next Year | $71.25 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.24 |
| 52 Week High | $4.18 | $3.00 |
| Indicator | UXIN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 32.02 | 22.76 |
| Support Level | N/A | N/A |
| Resistance Level | $1.27 | $1.99 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 15.76 | 2.08 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.